Table 1.

Baseline characteristics.

	Riluzole (n = 22)	Placebo (n = 21)	P value
Age (years) at disease onset (mean ± SD)	38.2 ± 9.84	32.4 ± 7.85	0.042
Disease duration (months) (mean ± SD)	6.9 ± 4.5	8.2 ± 5.4	0.54
% Females	77.3%	66.7%	0.44
% Nonwhites	4.5%	0%	0.32
% Hispanics	9.1%	14.3%	0.60
Median EDSS (range)	2.0 (0, 4.0)	2.0 (0, 5.5)	0.36
Normalized brain parenchymal volume (mean ± SD)	1620 ± 119	1660 ± 117	0.27
Normalized cerebrospinal fluid volume (mean ± SD)	439 ± 39.1	412 ± 37.9	0.050
Normalized gray matter volume (mean ± SD)	893 ± 67.3	924 ± 72.2	0.14
Normalized normal-appearing white matter volume (mean ± SD)	724 ± 68.3	736 ± 55.8	0.54
% with enhancing scans	36.4%	23.8%	0.62
Normalized lesion volume (mean ± SD)	7.56 ± 9.37	4.01 ± 4.67	0.21
T2 lesion load (mean ± SD)	5.7 ± 7.15	2.84 ± 2.92	0.25
MSFC (mean ± SD)	0.161 ± 0.392	−0.138 ± 1.03	1.00
Total RNFL (mean ± SD, micrometers)	183 ± 22.1	199 ± 24.2	0.043
SDMT (mean ± SD correct)	59 ± 9	56.8 ± 9.93	0.55